title: Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
abstract: Anticancer treatment has evolved enormously over the last decade. Drugs targeting receptor tyrosine kinases, VEGFR and EGFR have changed the treatment landscape of certain cancers and have shifted the theme of anticancer therapy toward personalized care. However, these newer agents also come with unique side-effect profiles not seen with conventional chemotherapy including serious cardiovascular adverse effects. Hence, meticulous understanding of the adverse effects is crucial in maximizing clinical benefits and minimizing detrimental effects of these newer drugs. We have reviewed the cardiovascular adverse effects of anti-VEGF therapy in this article.
authors.affiliation: Division of Hematology & Oncology, Department of Medicine, University of Arizona, Tucson, AZ, USA.
authors.forename: Srinath
authors.initials: S
authors.lastname: Sundararajan
authors.affiliation: Division of Hematology & Oncology, Department of Medicine, University of Arizona, Tucson, AZ, USA.
authors.forename: Abhijeet
authors.initials: A
authors.lastname: Kumar
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Mugilan
authors.initials: M
authors.lastname: Poongkunran
authors.affiliation: Division of Cardiology, Department of Medicine, University of Arizona, Tucson, AZ, USA.
authors.forename: Arun
authors.initials: A
authors.lastname: Kannan
authors.affiliation: University of Nevada School of Medicine & US Oncology/Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D019468:Disease Management; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A
keywords: adverse effects; angiogenesis inhibitors; anti-VEGF therapy; cardiovascular; tyrosine kinase inhibitors